213 related articles for article (PubMed ID: 15291376)
1. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?
Wehling M
Clin Ther; 2004; 26 Suppl A():A21-7. PubMed ID: 15291376
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of olmesartan medoxomil.
Brunner HR; Laeis P
J Hypertens Suppl; 2003 May; 21(2):S43-6. PubMed ID: 12929907
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and tolerability of olmesartan.
Brunner HR
Clin Ther; 2004; 26 Suppl A():A28-32. PubMed ID: 15291377
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan medoxomil: an angiotensin II-receptor blocker.
Brousil JA; Burke JM
Clin Ther; 2003 Apr; 25(4):1041-55. PubMed ID: 12809956
[TBL] [Abstract][Full Text] [Related]
6. Olmesartan medoxomil for the treatment of hypertension in children and adolescents.
Tocci G; Volpe M
Vasc Health Risk Manag; 2011; 7():177-81. PubMed ID: 21490943
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Chrysant SG; Chrysant GS
Expert Opin Pharmacother; 2004 Mar; 5(3):657-67. PubMed ID: 15013933
[TBL] [Abstract][Full Text] [Related]
8. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Gardner SF; Franks AM
Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
[TBL] [Abstract][Full Text] [Related]
9. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
Brunner HR
J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
[TBL] [Abstract][Full Text] [Related]
10. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
Chrysant SG; Germino FW; Neutel JM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):375-89. PubMed ID: 23116225
[TBL] [Abstract][Full Text] [Related]
11. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
Nussberger J; Koike H
Clin Ther; 2004; 26 Suppl A():A12-20. PubMed ID: 15291375
[TBL] [Abstract][Full Text] [Related]
12. The role of olmesartan medoxomil in the management of hypertension.
Unger T; McInnes GT; Neutel JM; Böhm M
Drugs; 2004; 64(24):2731-9. PubMed ID: 15563246
[TBL] [Abstract][Full Text] [Related]
13. Olmesartan medoxomil: recent clinical and experimental acquisitions.
Destro M; Preti P; D'Ospina A; Christian Achiri NN; Ricci AR; Cagnoni F
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1149-57. PubMed ID: 19689219
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
Ewald S; vor dem Esche J; Uen S; Neikes F; Vetter H; Mengden T
Clin Drug Investig; 2006; 26(8):439-46. PubMed ID: 17163276
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Punzi HA
Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):229-39. PubMed ID: 19296759
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.
Wells TG; Blowey DL; Sullivan JE; Blumer J; Sherbotie JR; Song S; Rohatagi S; Heyrman R; Salazar DE
Paediatr Drugs; 2012 Dec; 14(6):401-9. PubMed ID: 22880942
[TBL] [Abstract][Full Text] [Related]
17. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Mallion JM; Heagerty A; Laeis P
J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
[TBL] [Abstract][Full Text] [Related]
18. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
19. Olmesartan medoxomil.
Warner GT; Jarvis B
Drugs; 2002; 62(9):1345-53; discussion 1354-6. PubMed ID: 12076183
[TBL] [Abstract][Full Text] [Related]
20. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
